Zanidatamab + Evorpacept

Phase 1/2Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HER2-expressing Cancers

Conditions

HER2-expressing Cancers

Trial Timeline

Sep 15, 2021 → Sep 30, 2025

NCT ID

NCT05027139

About Zanidatamab + Evorpacept

Zanidatamab + Evorpacept is a phase 1/2 stage product being developed by Jazz Pharmaceuticals for HER2-expressing Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT05027139. Target conditions include HER2-expressing Cancers.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05027139	Phase 1/2	Completed	Sep 15, 2021	Sep 30, 2025	HER2-expressing Cancers

Competing Products

6 competing products in HER2-expressing Cancers

See all competitors

Product	Company	Stage	Hype Score
SHR-4602	Jiangsu Hengrui Medicine	Phase 2	42
SHR-A1811 combined with Pyrotinib. + SHR-A1811 combined with other antitumor therapies	Jiangsu Hengrui Medicine	Phase 1/2	39
VIR-5818 + pembrolizumab	Merck	Phase 1/2	39
ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine	Jazz Pharmaceuticals	Phase 2	32
ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib	Jazz Pharmaceuticals	Phase 1	26
ZW49	Zymeworks	Phase 1	23